Akebia Therapeutics Company Profile (NASDAQ:AKBA)

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company's segment is the business of developing and commercializing proprietary therapeutics based on HIF biology. The Company is involved in developing its lead product candidate, vadadustat, as an oral therapy for the treatment of anemia in chronic kidney disease (CKD) subjects not on dialysis and in subjects on dialysis. Its other clinical candidate, AKB-6899, is designed as a small molecule HIF prolyl-hydroxylase (HIF-PH) inhibitor with therapeutic benefit in oncology and ophthalmology. The Company is engaged in conducting approximately two global Phase III studies for the treatment of anemia in non-dialysis dependent patients, and over two Phase III studies for the treatment of anemia in dialysis-dependent CKD patients.

Industry, Sector and Symbol:

• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Exchange: NASDAQ
• Symbol: AKBA
• CUSIP:

Key Metrics:

• Previous Close: $9.09
• 50 Day Moving Average: $8.43
• 200 Day Moving Average: $8.62
• 52-Week Range: $7.00 - $13.20
• Trailing P/E Ratio: N/A
• Foreward P/E Ratio: -2.24
• P/E Growth: 0.00
• Market Cap: $166.16M
• Outstanding Shares: 18,300,000
• Beta: 0.8

Profitability:

• Return on Equity: -69.90%
• Return on Assets: -56.09%

Debt:

• Current Ratio: 9.20%
• Quick Ratio: 9.20%

Additional Links:

• Visit Akebia Therapeutics' Official Website
• View AKBA on Google Finance
• View AKBA on Yahoo Finance
• View AKBA's Company Profile on Reuters
• Search for Akebia Therapeutics Inc. on Google

Companies Related to Akebia Therapeutics:

• Heron Therapeutics (NASDAQ:HRTX)
• Albany Molecular Research (NASDAQ:AMRI)
• LHC Group (NASDAQ:LHCG)
• Anika Therapeutics (NASDAQ:ANIK)
• Adeptus Health (NYSE:ADPT)
• Civitas Solutions (NYSE:CIVI)
• Novadaq Technologies (NASDAQ:NVDQ)
• Cerus Corp. (NASDAQ:CERS)
• Aimmune Therapeutics (NASDAQ:AIMT)
• NantKwest (NASDAQ:NK)

Earnings

Earnings History for Akebia Therapeutics (NASDAQ:AKBA)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call	Details
11/7/2016
8/8/2016		($0.57)	($0.95)			View	N/A
3/14/2016	Q415	($0.28)	($0.66)	$11.60 million		View	Listen
11/9/2015	Q3	($0.52)	($0.68)			View	N/A
8/11/2015	Q215	($0.51)	($0.40)			View	N/A
5/11/2015		($0.57)	($0.53)			View	N/A
3/4/2015	Q414	($0.66)	($0.52)			View	N/A
11/10/2014	Q314	($0.45)	($0.47)			View	N/A
8/11/2014		($0.34)	($0.39)			View	N/A
5/12/2014		($0.38)	($0.04)			View	N/A

(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Akebia Therapeutics (NASDAQ:AKBA)

Dividends

Dividend History for Akebia Therapeutics (NASDAQ:AKBA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Akebia Therapeutics (NASDAQ:AKBA)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Details
7/6/2016	Duane Nash	Director	Sell	1,980	$7.48	$14,810.40
7/5/2016	Nicole R. Hadas	SVP	Sell	1,557	$7.47	$11,630.79
4/4/2016	Michel Dahan	SVP	Sell	1,401	$9.41	$13,183.41
10/2/2015	Nicole R Hadas	SVP	Sell	1,484	$8.67	$12,866.28
7/2/2015	Nicole R Hadas	SVP	Sell	1,484	$9.54	$14,157.36
4/22/2015	Muneer A Satter	Director	Buy	420,000	$8.25	$3,465,000.00
4/2/2015	Nicole R Hadas	SVP	Sell	1,483	$9.09	$13,480.47
1/2/2015	Nicole R Hadas	VP	Sell	1,715	$11.46	$19,653.90
12/29/2014	John P Butler	CEO	Buy	1,000	$11.57	$11,570.00
12/26/2014	Duane Nash	Director	Sell	11,933	$11.23	$134,007.59
12/22/2014	John P Butler	CEO	Buy	1,000	$11.92	$11,920.00
12/15/2014	John P Butler	CEO	Buy	1,000	$11.34	$11,340.00
12/2/2014	Ronald C Renaud Jr	Director	Buy	5,000	$11.92	$59,600.00
11/26/2014	Jason Amello	CFO	Buy	1,000	$13.22	$13,220.00
11/25/2014	Muneer A Satter	Director	Buy	5,000	$13.18	$65,900.00
11/24/2014	Muneer A Satter	Director	Buy	5,000	$13.88	$69,400.00
11/21/2014	Muneer A Satter	Director	Buy	5,000	$14.73	$73,650.00
11/20/2014	Muneer A Satter	Director	Buy	5,000	$14.70	$73,500.00
11/19/2014	Muneer A Satter	Director	Buy	5,000	$14.85	$74,250.00
11/18/2014	Muneer A Satter	Director	Buy	5,000	$13.84	$69,200.00
11/17/2014	Muneer A Satter	Director	Buy	5,000	$12.94	$64,700.00
11/14/2014	Muneer A Satter	Director	Buy	5,000	$11.91	$59,550.00
11/13/2014	Muneer A Satter	Director	Buy	5,000	$11.56	$57,800.00
11/12/2014	John P Butler	CEO	Buy	1,000	$10.31	$10,310.00
11/12/2014	Muneer A Satter	Director	Buy	5,000	$11.90	$59,500.00
3/25/2014	A/S Novo	Insider	Buy	182,590	$17.00	$3,104,030.00
3/25/2014	Jason Amello	CFO	Buy	4,000	$17.00	$68,000.00
3/25/2014	John P Butler	CEO	Buy	13,850	$17.00	$235,450.00
3/25/2014	Muneer A Satter	Director	Buy	91,295	$17.00	$1,552,015.00

(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Akebia Therapeutics (NASDAQ:AKBA)

Date	Headline
	Akebia Therapeutics (AKBA) Announces Publication of Positive HIF Treatments Data in Renal Anemia - StreetInsider.com (NASDAQ:AKBA) www.streetinsider.com - September 26 at 3:23 PM
	Akebia Therapeutics : Announces Publication Highlighting Potential Benefits of HIF Treatments for Patients with Renal Anemia (NASDAQ:AKBA) www.4-traders.com - September 26 at 9:44 AM
	Akebia Announces Publication Highlighting Potential Benefits of HIF Treatments for Patients with Renal Anemia (NASDAQ:AKBA) www.publicnow.com - September 26 at 9:44 AM
	Stock Update on Earnings & Estimates for Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Frisco Fastball (NASDAQ:AKBA) friscofastball.com - September 22 at 9:17 AM
	AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:AKBA) biz.yahoo.com - September 21 at 9:54 AM
	Shares Of Akebia Therapeutics, Inc. (NASDAQ:AKBA) Expected To Hit $26 - Investor Newswire (NASDAQ:AKBA) www.investornewswire.com - September 20 at 3:25 PM
	Akebia Therapeutics (AKBA) Reports Publication of Strong Vadadustat Phase 2 Data in CKD-Related Anemia - StreetInsider.com (NASDAQ:AKBA) www.streetinsider.com - September 20 at 9:13 AM
	Akebia Therapeutics : Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease (NASDAQ:AKBA) www.4-traders.com - September 19 at 4:20 PM
	Akebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease (NASDAQ:AKBA) www.publicnow.com - September 19 at 4:20 PM
	How Analysts Rated Akebia Therapeutics Inc (NASDAQ:AKBA) Last Week? - Post News (NASDAQ:AKBA) www.kentuckypostnews.com - September 16 at 3:25 PM
	Akebia Therapeutics, Inc. :AKBA-US: Earnings Analysis: Q2, 2016 By the Numbers : September 14, 2016 (NASDAQ:AKBA) www.capitalcube.com - September 14 at 3:25 PM
	Akebia Therapeutics Incorporated (NASDAQ:AKBA) Shorted Shares Increased 1.25% After Market Selling - Frisco Fastball (NASDAQ:AKBA) friscofastball.com - September 14 at 9:11 AM
	Sell-side is Weighing in on Akebia Therapeutics, Inc. (NASDAQ:AKBA) Earnings & Targets - Frisco Fastball (NASDAQ:AKBA) friscofastball.com - September 9 at 8:11 AM
	Akebia to Present at Upcoming Investor Conferences - Yahoo Finance (NASDAQ:AKBA) finance.yahoo.com - September 8 at 11:43 AM
	Akebia to Present at Upcoming Investor Conferences (NASDAQ:AKBA) www.publicnow.com - September 6 at 8:31 PM
	Stock Struggling for the Quarter: Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Post News (NASDAQ:AKBA) www.kentuckypostnews.com - September 4 at 3:22 PM
	Can Shares Of Akebia Therapeutics, Inc. (NASDAQ:AKBA) Get To $26? - Investor Newswire (NASDAQ:AKBA) www.investornewswire.com - August 29 at 4:02 PM
	Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Expected To Post EPS Of $-1.25 - RealistInvestor.com (NASDAQ:AKBA) www.realistinvestor.com - August 29 at 4:02 PM
	New Market Research Report: Akebia Therapeutics, Inc. (AKBA) - Financial and Strategic SWOT Analysis Review (NASDAQ:AKBA) www.live-pr.com - August 26 at 3:24 PM
	Akebia Therapeutics, Inc. (NASDAQ:AKBA) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:AKBA) www.investornewswire.com - August 22 at 3:27 PM
	Akebia Therapeutics : Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients (NASDAQ:AKBA) www.4-traders.com - August 22 at 8:12 AM
	7:04 am Akebia Therapeutics announces the publication of an analysis indicating persistently greater mortality in dialysis-dependent chronic kidney disease patients with agent hyporesponse (NASDAQ:AKBA) finance.yahoo.com - August 22 at 8:12 AM
	Akebia Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients (NASDAQ:AKBA) www.publicnow.com - August 22 at 8:12 AM
	AKEBIA THERAPEUTICS, INC. Financials (NASDAQ:AKBA) finance.yahoo.com - August 17 at 3:26 PM
	Analysts See Akebia Therapeutics, Inc. (NASDAQ:AKBA) Reporting EPS Of $-1.25 - RealistInvestor.com (NASDAQ:AKBA) www.realistinvestor.com - August 16 at 3:25 PM
	Will Akebia Therapeutics, Inc. (NASDAQ:AKBA) Hit $26 Price Target? - Investor Newswire (NASDAQ:AKBA) www.investornewswire.com - August 15 at 3:27 PM
	Calculating The Impact Of Akebia Therapeutics Inc (AKBA)’s Pivotals (NASDAQ:AKBA) www.insidermonkey.com - August 12 at 3:36 PM
	Why Akebia Therapeutics (AKBA) Could Be Positioned for a Slump (NASDAQ:AKBA) finance.yahoo.com - August 12 at 11:58 AM
	Calculating The Impact Of Akebia Therapeutics Inc (NASDAQ:AKBA)’s Pivotals (NASDAQ:AKBA) marketexclusive.com - August 11 at 3:26 PM
	Noteworthy Tuesday Option Activity: AKBA, LGF, D (NASDAQ:AKBA) www.stockoptionschannel.com - August 9 at 4:28 PM
	Akebia Initiates INNO2VATE Phase 3 Program for Vadadustat in Dialysis Patients With Anemia Related to Chronic Kidney Disease (NASDAQ:AKBA) ih.advfn.com - August 9 at 4:28 PM
	Brean Sees Huge Upside In Akebia Shares (NASDAQ:AKBA) www.benzinga.com - August 9 at 4:28 PM
	Akebia Therapeutics : reports 2Q loss (NASDAQ:AKBA) www.4-traders.com - August 9 at 4:28 PM
	Akebia Announces Second Quarter 2016 Financial Results (NASDAQ:AKBA) www.biospace.com - August 9 at 4:28 PM
	Akebia's Market Potential Undervalued By The Street, Says JMP (NASDAQ:AKBA) finance.yahoo.com - August 9 at 4:28 PM
	Akebia misses by $0.38 - Seeking Alpha (NASDAQ:AKBA) seekingalpha.com - August 8 at 8:52 PM
	Akebia Therapeutics reports 2Q loss (NASDAQ:AKBA) sg.finance.yahoo.com - August 8 at 8:52 PM
	Akebia Therapeutics Appoints Scott A. Canute to its Board of Directors - Business Wire (press release) (NASDAQ:AKBA) www.businesswire.com - August 2 at 9:01 PM
	AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Fi (NASDAQ:AKBA) biz.yahoo.com - August 2 at 9:01 PM
	Akebia Therapeutics Appoints Scott A. Canute to its Board of Directors (NASDAQ:AKBA) www.publicnow.com - August 2 at 9:01 PM
	AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:AKBA) biz.yahoo.com - July 28 at 4:07 PM
	Akebia Therapeutics Inc. (AKBA) Jumps 5.4% on July 27 - Equities.com (NASDAQ:AKBA) www.equities.com - July 28 at 12:03 PM
	New Broker Ratings For Akebia Therapeutics, Inc. (AKBA) - FTSE News (NASDAQ:AKBA) www.ftsenews.co.uk - July 25 at 8:11 AM
	Equity Roundup: Stock Performance Focus on Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Press Telegraph (NASDAQ:AKBA) presstelegraph.com - July 23 at 3:24 PM
	Akebia Therapeutics, Inc. (NASDAQ:AKBA): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:AKBA) www.engelwooddaily.com - July 21 at 3:24 PM
	Why Need to Watch: Invuity (NASDAQ:IVTY), Akebia Therapeutics (NASDAQ:AKBA), Taiwan Semiconductor ... - KC Register (NASDAQ:AKBA) www.kcregister.com - July 20 at 11:32 AM
	Akebia Therapeutics Incorporated (NASDAQ:AKBA) Short Interest Increased By 0.41% - Consumer Eagle (NASDAQ:AKBA) www.consumereagle.com - July 19 at 3:25 PM
	Is $26 Price Target Attainable For Akebia Therapeutics, Inc. (NASDAQ:AKBA)? - Investor Newswire (NASDAQ:AKBA) www.investornewswire.com - July 18 at 3:27 PM
	Shares Moving Down on the Week: Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Engelwood Daily (NASDAQ:AKBA) www.engelwooddaily.com - July 17 at 8:10 AM
	Are Analysts Bullish Akebia Therapeutics Inc (NASDAQ:AKBA) After Last Week? - Consumer Eagle (NASDAQ:AKBA) www.consumereagle.com - July 16 at 11:49 AM

Social

Akebia Therapeutics (NASDAQ:AKBA) Chart for Thursday, September, 29, 2016